Biocon launches GLP-1 drug Liraglutide in the UK

Liraglutide, a GLP-1 peptide for diabetes and obesity, has been introduced in the United Kingdom (UK) by Biocon Limited, a multinational biopharmaceutical business that leads innovation. In the UK, the medication-device combination will be sold under the brand names Biolide for chronic weight management (gSaxenda) and Liraglutide Biocon for diabetes (gVictoza).

The launch comes after Biocon Limited became the first generics business to receive permission for gLiraglutide in a major regulated market earlier this year after receiving approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), UK.

Biocon is still dedicated to solidifying its position as a major leader in this field, as GLP-1 medicines are anticipated to be a significant future growth driver for the firm.Drugs called lucagon-like peptide-1 (GLP-1) aid in lowering blood sugar levels and encouraging weight loss. These physiological hormones regulate meal-related glycaemic excursions by increasing insulin and inhibiting glucagon secretion. They have several effects on glucose, which are mediated by the GLP-1 receptors produced from gut enteroendocrine cells. In order to maximize nutrient absorption and prevent weight gain, GLP-1 also suppresses the activities of food intake and stomach emptying.

An injection of ligarglutide, a synthetic analogue of GLP-1 peptide, is given once daily. In 2009, the European Union authorized its usage for medical purposes, and in 2010, the United States did the same. For individuals who are overweight or obese and have at least one weight-related disease, ligarglutide was approved by the US FDA in 2014 and the European Medicines Agency a year later.